Skip to main content
. Author manuscript; available in PMC: 2024 May 22.
Published in final edited form as: J Rheumatol. 2019 Oct 1;47(10):1496–1505. doi: 10.3899/jrheum.190219

Figure 2: Known Groups: RAPID3 and PSAID by swollen joint count and by tender joint count.

Figure 2:

RAPID3 (a) and PSAID12 (b) scores are significantly different among patients with low disease activity (defined by a swollen joint count <4) compared to those with 4 or more swollen joints, suggesting that these measures differentiate between low and higher disease activity states. RAPID3 (c) and PSAID12 (d) scores are significantly different among patients with low disease activity (defined by a tender joint count <4) compared to those with 4 or more tender joints, suggesting that these measures differentiate between low and higher disease activity states.